Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Prilosec In "MUPS" Formulation Confirmed By AstraZeneca Exec

This article was originally published in The Tan Sheet

Executive Summary

AstraZeneca's proton pump inhibitor Prilosec (omeprazole) will switch to OTC status in the U.S. in the "multi-unit pellet system" (MUPS) dosage form, Exec VP-Gastrointestinal Franchise Martin Nicklasson, PhD, stated at a briefing for securities analysts in London Dec. 6.
Advertisement

Related Content

Oral Contraceptives Have Strong Rx-To-OTC Consumer Support - Survey
Oral Contraceptives Have Strong Rx-To-OTC Consumer Support - Survey
Oral Contraceptives Have Strong Rx-To-OTC Consumer Support - Survey
AstraZeneca Prilosec OTC Launch Anticipated For Second Quarter 2001
AstraZeneca Prilosec OTC Launch Anticipated For Second Quarter 2001

Topics

Advertisement
UsernamePublicRestriction

Register

PS090702

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel